Lantern Pharma (NASDAQ: LTRN) has reported its second-quarter 2026 operational and financial results, highlighting significant advancements in its AI-driven oncology pipeline and the strategic establishment of Open Medicine AI (OMAI) as a separate company. These developments underscore the company's commitment to leveraging artificial intelligence to transform cancer therapy development.
Emerging data from the Phase 2 HARMONIC trial demonstrated that LP-300's progression-free survival benefit deepened with longer treatment duration in patients with EGFR exon 21 L858R mutations, a subset of non-small cell lung cancer. The FDA reviewed key protocol amendments without objection, suggesting a favorable regulatory environment for the trial's continued progress. Meanwhile, the European Medicines Agency cleared an investigator-initiated Phase 1b/2 trial of LP-184, also known as zirdafulven, in biomarker-selected advanced bladder cancer, expanding the drug's potential applications. In the United States, the Patent and Trademark Office issued a Notice of Allowance for a three-gene patient-selection signature for LP-184, which could enhance precision medicine approaches.
A pivotal move in August was the establishment of OMAI as a wholly owned subsidiary, accompanied by board-approved commercial licensing agreements for the multi-agentic AI co-scientist platform previously launched as withZeta.ai. This platform is now commercially available as a subscription-based research tool for the global biomedical and drug development community, representing a new revenue stream for Lantern. By spinning out OMAI, Lantern aims to unlock value from its AI capabilities while maintaining strategic oversight.
Financially, Lantern reported a second-quarter loss from operations of approximately $3.5 million, a 25% improvement from the $4.7 million loss in the same period last year. Research and development expenses declined 42% to about $1.8 million, reflecting disciplined cost management. The net loss was approximately $7.1 million, or $0.57 per share, compared with $4.3 million, or $0.40 per share, a year earlier. The increase was largely due to approximately $3.6 million in warrant-related expenses, which are non-operational. As of June 30, 2026, the company held cash, cash equivalents, and marketable securities totaling approximately $7.4 million, providing a runway to continue its clinical programs.
Lantern Pharma is a clinical-stage precision oncology company that leverages AI, machine learning, and its proprietary RADR platform to accelerate the development of cancer therapies. Its pipeline includes LP-184, a novel acylfulvene, LP-284, a TC-NER targeting compound for hematologic and solid tumors, and LP-300, which is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, a wholly owned subsidiary focused on central nervous system malignancies.
The company's AI Center of Excellence in Bengaluru, India, and headquarters in Dallas, Texas, support its global operations. With the recent progress and strategic initiatives, Lantern Pharma is positioning itself to deliver innovative treatments to patients while creating value for shareholders. The full press release is available at https://nnw.fm/m9pULA.
